PLA2G6 and Parkinson disease: Currently existing transgenic PLA2g6 mouse models13, 14, 15, 16, 17, 18 appear to be unsuitable for PD studies, as they have impaired catalytic activity of PLA2g6, which we found to be unaffected in idPD patients.